ADMA Biologics, Inc. ADMA

$ADMA
Early trials of the experimental treatment indicated a 35% better chance of survival when convalescent plasma was used in "optimal patients" — which studies indicate are patients in the early stages of infection, before the virus invades the tissue and causes cell damage.
https://www.google.com/amp/s/www.cbsnews.com/amp/news/covid-convalescent-plasma-shortage/

$ADMA https://pennystocks.com/featured/2021/01/19/best-penny-stocks-analysts-buy-now-180-target-january-2021/

$ADMA Phase 3 results should me announced any day now.

$ADMA https://www.fiercebiotech.com/biotech/we-ve-learned-a-lot-about-covid-19-but-we-re-still-1st-inning-fierce-jpm-week

ADMA$ Perhaps in tonight’s JPM Healthcare Conference Takeda will provide an update on how much progress Takeda and ADMA and the Plasma Alliance have made in developing a hyperimmune globulin therapy for COVID-19.
https://www.businesswire.com/news/home/20210111005289/en/Takeda-to-Present-at-The-39th-Annual-J.P.-Morgan-Healthcare-Conference

$ADMA It’s the $1.99 special. This price won’t last long. Get it while you can.!

For comparison, other companies in the same industry with market capitalizations ranging between US$100m and US$400m had a median total CEO compensation of US$1.5m. This suggests that ADMA Biologics remunerates its CEO largely in line with the industry average. Moreover, Adam Grossman also holds US$2.1m worth of ADMA Biologics stock directly under their own name, which reveals to us that they have a significant personal stake in the company.
https://www.google.com/amp/s/simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/how-is-adma-biologics-nasdaqadma-ceo-compensated/amp

$ADMA https://www.google.com/amp/s/www.marketbeat.com/instant-alerts/nasdaq-adma-consensus-analyst-rating-2020-12/amp/

$ADMA https://pennystocks.com/featured/2020/12/09/best-penny-stocks-4-price-targets-up-to-419-december-9-2020/

“In early 2021, we hope to have the results from that phase three clinical trial available, at which time we'll work with regulators to see how we make this most effectively available to those in need,” says Dr. Kreil.
https://www.bioprocessonline.com/doc/covid-consortium-competitive-collaboration-on-a-plasma-derived-therapy-0001